{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:16:45Z","timestamp":1791400605201,"version":"4.3.3"},"reference-count":30,"publisher":"Impact Journals, LLC","issue":"43","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,10,25]]},"DOI":"10.18632\/oncotarget.12132","type":"journal-article","created":{"date-parts":[[2016,9,23]],"date-time":"2016-09-23T22:19:01Z","timestamp":1474669141000},"page":"70000-70010","source":"Crossref","is-referenced-by-count":63,"title":["Acquired resistance to venetoclax (ABT-199) in<i>t(14;18)<\/i>positive lymphoma cells"],"prefix":"10.18632","volume":"7","author":[{"given":"Juraj","family":"Bodo","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine, Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxian","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Durkin","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Souers","sequence":"additional","affiliation":[{"name":"Oncology Discovery, AbbVie, Inc., Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren C.","family":"Phillips","sequence":"additional","affiliation":[{"name":"Oncology Discovery, AbbVie, Inc., Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell R.","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D.","family":"Hsi","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2016,9,20]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/00001622-199609000-00004","article-title":"Current management of follicular lymphoma","volume":"8","author":"Lister","year":"1996","journal-title":"Curr Opin Oncol"},{"key":"2","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1126\/science.3874430","article-title":"Involvement of the bcl-2 gene in human follicular lymphoma","volume":"228","author":"Croce","year":"1985","journal-title":"Science"},{"key":"3","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.molcel.2010.01.025","article-title":"The BCL-2 family reunion","volume":"37","author":"Green","year":"2010","journal-title":"Mol Cell"},{"key":"4","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1177\/1947601911417177","article-title":"The Role of BH3-Only Proteins in Tumor Cell Development, Signaling, and Treatment","volume":"2","author":"Chipuk","year":"2011","journal-title":"Genes Cancer"},{"key":"5","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.2011.34.7898","article-title":"Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease","volume":"30","author":"McKeegan","year":"2012","journal-title":"J Clin Oncol"},{"key":"6","first-page":"02","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Jin","year":"2013","journal-title":"Nat Med"},{"key":"7","article-title":"Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia","author":"Zhu","year":"2015","journal-title":"N Engl J Med"},{"key":"8","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/0165-4608(93)90132-6","article-title":"A unique EBV-negative low-grade lymphoma line (WSU-FSCCL) exhibiting both t(14;18) and t(8;11)","volume":"70","author":"al-Katib","year":"1993","journal-title":"Cancer Genet Cytogenet"},{"key":"9","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/bjh.12711","article-title":"Milatuzumab and veltuzumab induce apoptosis through JNK signalling in an NF-kappaB dependent human transformed follicular lymphoma cell line","volume":"165","author":"Joshi","year":"2014","journal-title":"Br J Haematol"},{"key":"10","article-title":"Development of a flow cytometric method for quantification of BCL-2 family members in chronic lymphocytic leukemia and correlation with sensitivity to BCL-2 family inhibitors","author":"Tahir","year":"2016","journal-title":"Cytometry B Clin Cytom"},{"key":"11","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1083\/jcb.200507002","article-title":"p62\/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death","volume":"171","author":"Johansen","year":"2005","journal-title":"J Cell Biol"},{"key":"12","doi-asserted-by":"crossref","first-page":"6998","DOI":"10.1158\/0008-5472.CAN-13-0940","article-title":"Contribution of Bcl-2 phosphorylation to Bak binding and drug resistance","volume":"73","author":"Kaufmann","year":"2013","journal-title":"Cancer Res"},{"key":"13","doi-asserted-by":"crossref","first-page":"23681","DOI":"10.1074\/jbc.M100279200","article-title":"Novel role for JNK as a stress-activated Bcl2 kinase","volume":"276","author":"May","year":"2001","journal-title":"J Biol Chem"},{"key":"14","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1158\/1535-7163.1693.3.12","article-title":"Enhanced efficacy of therapy with antisense BCL-2 oligonucleotides plus anti-CD20 monoclonal antibody in scid mouse\/human lymphoma xenografts","volume":"3","author":"Joshi","year":"2004","journal-title":"Mol Cancer Ther"},{"key":"15","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2141.2008.07353.x","article-title":"Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma","volume":"143","author":"Younes","year":"2008","journal-title":"Br J Haematol"},{"key":"16","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1038\/sj.onc.1210365","article-title":"Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo\/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions","volume":"26","author":"Bonavida","year":"2007","journal-title":"Oncogene"},{"key":"17","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1182\/blood.V122.21.1789.1789","article-title":"The Single-Agent Bcl-2 Inhibitor ABT-199 (GDC-0199) In Patients With Relapsed\/Refractory (R\/R) Non-Hodgkin Lymphoma (NHL): Responses Observed In All Mantle Cell Lymphoma (MCL) Patients","volume":"122","author":"Roberts","year":"2013","journal-title":"Blood"},{"key":"18","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1172\/JCI28281","article-title":"Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737","volume":"117","author":"Letai","year":"2007","journal-title":"J Clin Invest"},{"key":"19","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/leu.2014.1","article-title":"Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199","volume":"28","author":"Huang","year":"2014","journal-title":"Leukemia"},{"key":"20","doi-asserted-by":"crossref","first-page":"6785","DOI":"10.1038\/sj.onc.1206792","article-title":"Phosphorylation of Bim-EL by Erk1\/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function","volume":"22","author":"Auberger","year":"2003","journal-title":"Oncogene"},{"key":"21","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/sj.leu.2405098","article-title":"Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway","volume":"22","author":"Andreeff","year":"2008","journal-title":"Leukemia"},{"key":"22","doi-asserted-by":"crossref","first-page":"13681","DOI":"10.1073\/pnas.251194298","article-title":"SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase","volume":"98","author":"Anderson","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"23","doi-asserted-by":"crossref","first-page":"e1593","DOI":"10.1038\/cddis.2014.525","article-title":"MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K\/AKT\/mTOR activation in lymphoid malignancies","volume":"6","author":"Almasan","year":"2015","journal-title":"Cell Death Dis"},{"key":"24","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.3324\/haematol.2013.088849","article-title":"The phosphatidylinositol-3-kinase inhibitor NVP-BKM120 overcomes resistance signals derived from microenvironment by regulating the Akt\/FoxO3a\/Bim axis in chronic lymphocytic leukemia cells","volume":"98","author":"Colomer","year":"2013","journal-title":"Haematologica"},{"key":"25","doi-asserted-by":"crossref","first-page":"6096","DOI":"10.1158\/1078-0432.CCR-09-0589","article-title":"Combined Bcl-2\/mammalian target of rapamycin inhibition leads to enhanced radiosensitization via induction of apoptosis and autophagy in non-small cell lung tumor xenograft model","volume":"15","author":"Lu","year":"2009","journal-title":"Clin Cancer Res"},{"key":"26","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1038\/onc.2011.104","article-title":"BH3 mimetics activate multiple pro-autophagic pathways","volume":"30","author":"Kroemer","year":"2011","journal-title":"Oncogene"},{"key":"27","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1002\/pros.22487","article-title":"Effect of dual inhibition of apoptosis and autophagy in prostate cancer","volume":"72","author":"DiPaola","year":"2012","journal-title":"Prostate"},{"key":"28","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1182\/blood-2003-03-0820","article-title":"NPM-ALK fusion kinase of anaplastic large-cell lymphoma regulates survival and proliferative signaling through modulation of FOXO3a","volume":"103","author":"Sternberg","year":"2004","journal-title":"Blood"},{"key":"29","doi-asserted-by":"publisher","first-page":"35202","DOI":"10.18632\/oncotarget.6051","article-title":"MCL-1-independent mechanisms of synergy between dual PI3K\/mTOR and BCL-2 inhibition in diffuse large B cell lymphoma","volume":"6","author":"Fruman","year":"2015","journal-title":"Oncotarget"},{"key":"30","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Talalay","year":"1984","journal-title":"Adv Enzyme Regul"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.12132","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,9]],"date-time":"2022-07-09T03:09:56Z","timestamp":1657336196000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.12132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,20]]},"references-count":30,"journal-issue":{"issue":"43","published-print":{"date-parts":[[2016,10,25]]}},"alternative-id":["12132","27661108"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.12132","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,20]]}}}